Quick Answer
Arcadia Biosciences, Inc. reported Diluted EPS of $1.71 per share (loss) for fiscal year 2025.
Arcadia Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.71 | +66.9% |
| 2024 | -$5.17 | +54.2% |
| 2023 | -$11.29 | +56.0% |
| 2022 | -$25.65 | +6.9% |
| 2021 | -$27.56 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.62 | +152.5% | +119.0% |
| June 30, 2025 | -$3.26 | -517.9% | -271.6% |
| March 31, 2025 | $1.90 | +206.7% | +261.0% |
| September 30, 2024 | -$1.18 | +37.6% | -251.3% |
| June 30, 2024 | $0.78 | +27.9% | +143.8% |
| March 31, 2024 | -$1.78 | +83.6% | +5.8% |
| September 30, 2023 | -$1.89 | +59.5% | -409.8% |
| June 30, 2023 | $0.61 | +109.0% | +105.6% |
- Arcadia Biosciences, Inc. showed an increase of +66.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Arcadia Biosciences, Inc.’s diluted eps has grown by 93.8% (from $27.56 per share (loss) to $1.71 per share (loss)).
- The most recent figure is from Arcadia Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: